Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 21;11(9):2561–2569. doi: 10.1111/1759-7714.13574

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

(a,b). Comparison of the overall survival (OS) (a) and recurrence‐free survival (RFS) (b) between DLL3 expression‐positive and expression‐negative LCNEC patients. (c,d). The comparison of the OS (c) and RFS (d) between LCNEC patients who underwent surgery with and without adjuvant chemotherapy. (a) () DLL3 positive (n = 26) five‐year OS: 46.2%, () DLL3 negative (n = 44) five‐year OS: 43.1%; (b) () DLL3 positive (n = 26) five‐year RFS: 38.5%, () DLL3 negative (n = 44) five‐year RFS: 36.4%; (c) () Surgery + chemotherapy (n = 23) five‐year OS: 72.7%, () Surgery alone (n = 47) five‐year RFS: 29.5%; (d) () Surgery + chemotherapy (n = 23) five‐year RFS: 59.1%, () Surgery alone (n = 47) five‐year RFS: 29.5%.

Inline graphic — (a,b). Comparison of the overall survival (OS) (a) and recurrence‐free survival (RFS) (b) between DLL3 expression‐positive and expression‐negative LCNEC patients. (c,d). The comparison of the OS (c) and RFS (d) between LCNEC patients who underwent surgery with and without adjuvant chemotherapy. (a) () DLL3 positive (n = 26) five‐year OS: 46.2%, () DLL3 negative (n = 44) five‐year OS: 43.1%; (b) () DLL3 positive (n = 26) five‐year RFS: 38.5%, () DLL3 negative (n = 44) five‐year RFS: 36.4%; (c) () Surgery + chemotherapy (n = 23) five‐year OS: 72.7%, () Surgery alone (n = 47) five‐year RFS: 29.5%; (d) () Surgery + chemotherapy (n = 23) five‐year RFS: 59.1%, () Surgery alone (n = 47) five‐year RFS: 29.5%.